A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
Status:
Terminated
Trial end date:
2020-04-23
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose
escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough